Gravina Antonietta G, Pellegrino Raffaele, Facchiano Angela, Palladino Giovanna, Loguercio Carmelina, Federico Alessandro
Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Front Pharmacol. 2021 Dec 14;12:773320. doi: 10.3389/fphar.2021.773320. eCollection 2021.
Several evidences have shown how, in hemorrhoidal disease, phlebotonic flavonoid agents such as quercetin reduce capillary permeability by increasing vascular walls resistance, how rutin and vitamin C have antioxidant properties, and that has reparative properties towards the connective tissue. A retrospective study was designed in order to evaluate the efficacy and safety of a compound consisting of micronized flavonoids in combination with vitamin C and extracts of , , and for grade II and III hemorrhoidal disease. Data of 49 patients, over 18, who were following a free diet regimen, not on therapy with other anti-hemorrhoid agents, treated with a compound consisting of 450 mg of micronized diosmin, 300 mg of , 270 mg of micronized hesperidin, 200 mg of , 160 mg of vitamin C, 160 mg of , 140 mg of micronized quercetin, and 130 mg of micronized rutin (1 sachet or 2 tablets a day) for 7 days were collected. Hemorrhoid grade according to Goligher's scale together with anorectal symptoms (edema, prolapse, itching, thrombosis, burning, pain, tenesmus, and bleeding) both before treatment (T0) and after 7 days of therapy (T7) were collected. Primary outcomes were the reduction of at least one degree of hemorrhoids according to Goligher's scale assessed by proctological examination and compound safety. The secondary outcome was the reduction of anorectal symptoms assessed by questionnaires administered to patients. Forty-four patients (89.8%) presented a reduction in hemorrhoidal grade of at least one grade ( < 0.001). No adverse events with the use of the compound were noted. A significant reduction was observed in all anorectal symptoms evaluated ( < 0.05). No predictors of response to the compound were identified among the clinical and demographic variables collected. The compound analyzed was effective and safe for patients with grade II and III hemorrhoidal disease according to Goligher's scale.
多项证据表明，在痔病中，槲皮素等促静脉循环类黄酮剂如何通过增加血管壁阻力来降低毛细血管通透性，芦丁和维生素C如何具有抗氧化特性，以及其对结缔组织具有修复特性。本研究设计了一项回顾性研究，以评估一种由微粉化类黄酮与维生素C以及[此处原文缺失具体植物名称]、[此处原文缺失具体植物名称]和[此处原文缺失具体植物名称]提取物组成的化合物对II级和III级痔病的疗效和安全性。收集了49例18岁以上患者的数据，这些患者遵循自由饮食方案，未接受其他抗痔药物治疗，接受了一种由450毫克微粉化地奥司明、300毫克[此处原文缺失具体成分]、270毫克微粉化橙皮苷、200毫克[此处原文缺失具体成分]、160毫克维生素C、160毫克[此处原文缺失具体成分]、140毫克微粉化槲皮素和130毫克微粉化芦丁组成的化合物（每天1袋或2片）治疗7天。收集了治疗前（T0）和治疗7天后（T7）根据Goligher分级法的痔分级以及肛肠症状（水肿、脱垂、瘙痒、血栓形成、灼痛、疼痛、里急后重和出血）。主要结局是通过直肠检查评估的根据Goligher分级法痔至少降低一级以及化合物的安全性。次要结局是通过向患者发放问卷评估的肛肠症状的减轻。44例患者（89.8%）痔分级至少降低了一级（P<0.001）。使用该化合物未观察到不良事件。在所有评估的肛肠症状中均观察到显著减轻（P<0.05）。在所收集的临床和人口统计学变量中未发现对该化合物反应的预测因素。根据Goligher分级法，所分析的化合物对II级和III级痔病患者有效且安全。
